These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24753447)

  • 21. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
    Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
    J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.
    Tanaka K; Eskin A; Chareyre F; Jessen WJ; Manent J; Niwa-Kawakita M; Chen R; White CH; Vitte J; Jaffer ZM; Nelson SF; Rubenstein AE; Giovannini M
    Clin Cancer Res; 2013 Jul; 19(14):3856-70. PubMed ID: 23714726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
    Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
    Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
    Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
    Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
    Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
    Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
    Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
    J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
    Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
    Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
    Jia JM; Liu F; Xu XL; Guo XK; Jiang F; Cherfaoui B; Sun HP; You QD
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1557-61. PubMed ID: 24582477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
    Wang C; Barluenga S; Koripelly GK; Fontaine JG; Chen R; Yu JC; Shen X; Chabala JC; Heck JV; Rubenstein A; Winssinger N
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3836-40. PubMed ID: 19410458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells.
    Piven YA; Yastrebova MA; Khamidullina AI; Scherbakov AM; Tatarskiy VV; Rusanova JA; Baranovsky AV; Zinovich VG; Khlebnicova TS; Lakhvich FA
    Bioorg Med Chem; 2022 Jan; 53():116521. PubMed ID: 34844036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
    Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
    Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors.
    Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A
    J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.